Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2003
06/17/2003US6579849 Antibiotic peptides from bovine milk
06/17/2003US6579847 Method and apparatus for vascular neuromuscular blockade
06/17/2003US6579723 Method of recovering highly purified vWF or factor VIII/vWF-complex
06/17/2003US6579702 Mammalian tolloid-like gene and protein
06/17/2003US6579700 Neuropeptide Y (NPY); isolated peptide of given amino acid sequence; may be useful in regulating central and peripheral nervous and endocrine systems
06/17/2003US6579697 Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
06/17/2003US6579696 Comprising diaminobutyric acid having a gamma amino group and amino acid selected from cysteine, alanine and lysine; use in prevention and treatment of sepsis
06/17/2003US6579695 Phosphopantetheinyl transferases and uses thereof
06/17/2003US6579692 Method of screening apoptosis inducing substances
06/17/2003US6579691 DNA sequence encoding a neuronal protein kinase (NPK) which phosphorylates tau proteins as well as other microtubule associated proteins (MAPs) in positions crucial for the binding to microtubules, alzheimers disease, antitumor
06/17/2003US6579689 Modulation of γ-secretase activity
06/17/2003US6579684 Assay of YKL-40 as a marker for cancer
06/17/2003US6579683 A ligand which is a member of Ephrin family of Eph family receptor interactive protein has been shown to be expressed by arterial endothelial cells but not by venous endothelial cell, useful for distinguishing target artieris and veins
06/17/2003US6579678 Identifying evolved polynucleotides using recursive sequence recombination; recombining overlapping nucleotide sequences; screening for desired property; use in correlating different combinations of mutations with a desired result
06/17/2003US6579531 Method for treating heart disease and cardiovascular disease in diabetic and non-diabetic patients
06/17/2003US6579526 Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes
06/17/2003US6579525 Pharmaceutical compositions comprising erythropoietin for treatment of cancer
06/17/2003US6579523 Transplants for myocardial scars
06/17/2003US6579522 Replication deficient adenoviral TNF vector
06/17/2003US6579521 Methods of therapy for HIV infection
06/17/2003US6579520 IL-17 related mammalian cytokine polypeptides (IL-17E)
06/17/2003CA2251928C Antifungal compositions
06/17/2003CA2129820C Dna sequences encoding novel growth/differentiation factors
06/17/2003CA2123315C Therapeutic agents which are antagonists or partial agonists of human interleukin 4
06/17/2003CA2118816C Composition for introducing nucleic acid complexes into higher eucaryotic cells
06/17/2003CA2100462C Non-depleting cd4-specific monoclonal antibodies for the treatment of insulin-dependent diabetes mellitus (iddm)
06/17/2003CA2072249C Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
06/17/2003CA2046654C Radiolabeled proteins for diagnostic or therapeutic use
06/17/2003CA1341432C Variants of plasminogen activators and processes for their production
06/17/2003CA1341431C Immunotherapy for aids patients
06/13/2003WO2003047602A1 Immunostimulatory oligodeoxynucleotides
06/13/2003CA2452909A1 Immunostimulatory oligodeoxynucleotides
06/12/2003WO2003048780A2 Uses of aldose-1-epimerase (mutarotase) for diagnosis and therapy of inflammatory diseases and sepsis
06/12/2003WO2003048775A2 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
06/12/2003WO2003048735A2 Processes for the measurement of the potency of glatiramer acetate
06/12/2003WO2003048394A1 Polynucleotides and polypeptides associated with the development of osteoarthritis
06/12/2003WO2003048390A1 A process for the preparation of a non-toxic anthrax vaccine
06/12/2003WO2003048383A2 Effectors of innate immunity
06/12/2003WO2003048379A1 T-bet compositions and methods of use thereof
06/12/2003WO2003048376A2 Modulation of immune-cell related disorders using il-1hy2
06/12/2003WO2003048375A1 Hybrid glycosylated products and their production and use
06/12/2003WO2003048362A2 Suppression of polymeric alleles
06/12/2003WO2003048361A2 P55pik
06/12/2003WO2003048360A1 NOVEL PROTEINS BINDING TO MAMMALIAN TARGET OF RAPAMYCIN (mTOR) AND GENES THEREOF
06/12/2003WO2003048358A1 Adipocyte differentiation-associated gene and protein
06/12/2003WO2003048354A1 Protein-decomposing/eliminating enzyme and utilization thereof
06/12/2003WO2003048352A2 Histone h3 methyltransferase polypeptide
06/12/2003WO2003048334A2 Immunocytokines with modulated selectivity
06/12/2003WO2003048333A2 Endorepellin compositions and methods for inhibiting angiogenesis
06/12/2003WO2003048331A2 Antisense modulation of phospholipid scramblase 4 expression
06/12/2003WO2003048328A2 Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
06/12/2003WO2003048326A2 Methods and materials relating to novel polypeptides and polynucleotides
06/12/2003WO2003048324A2 Antisense modulation of phospholipid scramblase 3 expression
06/12/2003WO2003048315A2 Antisense modulation of mdm2 expression
06/12/2003WO2003048303A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
06/12/2003WO2003048297A2 Regulation of human atp-binding cassette transporter 1 like-protein
06/12/2003WO2003048210A1 Fusion protein having enhanced in vivo erythropoietin activity
06/12/2003WO2003048206A2 Growth hormone agonist peptides and their uses
06/12/2003WO2003048205A2 Novel proteins with il-6 inhibiting activity
06/12/2003WO2003048201A1 Antimicrobial bolisin peptides
06/12/2003WO2003048200A1 Nuclear protein 'shoca' - a component of the wnt signalling pathway
06/12/2003WO2003048199A1 Cytotoxic protein and utilization thereof
06/12/2003WO2003048196A2 Means and methods for diagnosing and treating craniofacial malformations
06/12/2003WO2003048195A2 Glucose dependant release of insulin from glucose sensing insulin derivatives
06/12/2003WO2003048193A2 GIPs, A FAMILY OF POLYPEPTIDES WITH TRANSCRIPTION FACTOR ACTIVITY THAT INTERACT WITH GOODPASTURE ANTIGEN BINDING PROTEIN
06/12/2003WO2003048192A1 Novel peptides and medicinal uses thereof
06/12/2003WO2003048190A2 Acyclovir-peptide analogs
06/12/2003WO2003048188A2 15603, a human ion channel family member
06/12/2003WO2003048187A2 Peptides and use thereof in therapeutic agents against hiv infection
06/12/2003WO2003048183A2 Method for obtaining oestrogen from mare urine
06/12/2003WO2003048127A1 Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation
06/12/2003WO2003048119A2 Method of producing n-[(2s)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl]-l-leucyl-l-tert-leucine n-methylamide and intermediate thereof
06/12/2003WO2003047635A1 Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
06/12/2003WO2003047624A1 Cell migration inhibitor
06/12/2003WO2003047621A1 CELL PROLIFERATION INHIBITOR CONTAINING ANTI-PepT ANTIBODY
06/12/2003WO2003047619A2 Adjuvanted antigenic meningococcal compositions
06/12/2003WO2003047618A2 Immunotherapeutic methods and systems
06/12/2003WO2003047616A1 Migration of hematopoietic stem cells and progenitor cells to th e liver
06/12/2003WO2003047615A1 Dexar agonists and antagonists for use in the treatment of metabolic disorders
06/12/2003WO2003047614A1 Agonist and antagonists of redax for the treatment of metabolic disorders
06/12/2003WO2003047613A1 Use of c-jun or c-jun activating agents such as uv or c-jun n-terminal kinases (junks) for treating cancer
06/12/2003WO2003047612A1 The use of cck-8 for the preparation of a pharmaceutical composition against inflammatory disorders
06/12/2003WO2003047611A2 Ptp10d, tec and edtp involved in triglycerid-metabolism
06/12/2003WO2003047589A1 Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
06/12/2003WO2003047586A1 Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
06/12/2003WO2003047577A2 Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses
06/12/2003WO2003047576A1 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
06/12/2003WO2003047568A1 N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity
06/12/2003WO2003047553A1 Synthesis of small particles
06/12/2003WO2003047543A1 Methods for the treatment of hyperpigmentation of skin
06/12/2003WO2003047533A2 Composition for treating the surface of the skin
06/12/2003WO2003047532A2 Compositions and methods for the therapeutic use of an atonal-associated sequence for a gastrointestinal condition
06/12/2003WO2003047530A2 Storage-stable fibrin sealant
06/12/2003WO2003047526A2 Cell adhesion and extracellular matrix proteins
06/12/2003WO2003047525A2 Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
06/12/2003WO2003047524A2 Methods and compositions for modulating the immune system and uses thereof
06/12/2003WO2003047518A2 Cyclodextrin grafted biocompatible amphiphilic polymer and methods of preparation and use thereof
06/12/2003WO2003047514A2 Reducing myelin-mediated inhibition of axon regeneration
06/12/2003WO2003047507A2 Factor viii c2 domain variants
06/12/2003WO2003047506A2 Peptide agonists of prostate-specific antigen, and uses therefor
1 ... 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 ... 3163